Elicio Therapeutics Inc (ELTX) — Titan Protect Analysis

ELTX

Elicio Therapeutics Inc

Healthcare · ·

$13.26

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$223M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.64

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-1,076.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$17.50

+32% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 2 analysts covering this stock

About Elicio Therapeutics Inc

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven ca

https://elicio.com

Country: United States Employees: 33 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.770

Good returns relative to risk taken

Kelly Fraction

0.0522

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.538

Acceptable balance between returns and drawdown risk

Annual Return

32.3%

Historical annualised return based on price data

Max Drawdown

-60.1%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$14.93

11% below the year high

52W Low

$7.37

80% above the year low

Avg Volume

132,490

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.36

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-23,488,000

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-40,185,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$17.50

Target Low

$17.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go